地舒单抗停药后使用唑来膦酸:重复给药是否比单次输注更有效?
本研究回顾性分析52例按欧洲钙化组织学会(ECTS)建议管理的患者,在地舒单抗(Dmab)停药后1个月给予唑来膦酸(ZOL),6个月后若C末端肽(CTX)≥280 ng/L则再次输注。75%患者重复输注,该组脊柱骨密度(BMD)显著下降(-5.5±5.6%),而CTX<280 ng/L组保持稳定(-0.1±5.5%,P=0.008)。结论认为在CTX水平未控制的患者中,间隔6个月两次ZOL输注不能预防BMD丢失和骨折。
要点
- 地舒单抗停药后按ECTS建议重复唑来膦酸,75%患者接受了第二次输注。
- 重复输注组脊柱BMD下降-5.5±5.6%,CTX<280 ng/L组稳定在-0.1±5.5%(P=0.008)。
- 所有骨折患者(9.6%)均接受过>5次地舒单抗注射和2次唑来膦酸输注。
核心结论
- 在地舒单抗停药后CTX水平未控制的患者中,间隔6个月两次唑来膦酸输注不能预防BMD丢失和骨折。
研究设计与样本
- 回顾性研究,纳入52例按欧洲钙化组织学会(ECTS)建议管理的患者,地舒单抗停药后1个月给予唑来膦酸,6个月后若CTX≥280 ng/L则再次输注。
- 在地舒单抗停药后平均17个月评估BMD变化和骨折率。
主要发现
- 75%的患者重复了唑来膦酸输注;该组脊柱BMD显著下降(-5.5±5.6%),而CTX<280 ng/L组保持稳定(-0.1±5.5%,P=0.008)。
- 所有骨折患者(9.6%)均接受过>5次地舒单抗注射和2次唑来膦酸输注。
- 地舒单抗停药后BMD恶化与CTX t1相关(OR 2.9,IQR 1.3-6.6,P=0.009),也与地舒单抗治疗期间脊柱BMD增加经地舒单抗注射次数校正后相关(OR 3.0,IQR 1.2-7.2,P=0.014)。
- CTX t1>212 ng/L预测BMD丢失的敏感性为100%。
关键数值与推荐
- 欧洲钙化组织学会(ECTS)建议对CTX水平持续升高的患者重复给予唑来膦酸。
- 地舒单抗停药后6个月CTX≥280 ng/L时给予第二次唑来膦酸输注。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After denosumab (Dmab) discontinuation C-terminal telopeptide (CTX) levels increase, bone mineral density (BMD) decreases and multiple vertebral fractures (FX) may occur with relevant impacts on women's health. A sequential therapy with bisphosphonates is recommended, and the European Calcified Tissue Society (ECTS) proposed repeated zoledronate (ZOL) administrations in patients with persistently high CTX levels, although the efficacy of this schedule is unknown. In this retrospective study, we describe BMD changes and FX rate in 52 patients managed according to the ECTS recommendations. METHODS: We measured CTX levels and administered ZOL after 1 month from Dmab withdrawal (t0). After 6 months (t1), we administered a second ZOL infusion, if CTX levels were ≥280 ng/L. BMD changes and FX rate were assessed on average after 17 months from Dmab withdrawal. RESULTS: Seventy-five percent of patients repeated ZOL infusion. In this group, spine BMD declined significantly (-5.5 ± 5.6%), while it remained stable in the group with CTX levels <280 ng/L (-0.1 ± 5.5%, P = 0.008). All fractured patients (9.6%) had received >5 Dmab injections and 2 ZOL infusions. The BMD worsening after Dmab withdrawal was associated with CTX t1 [odds ratio (OR) 2.9, interquartile range (IQR) 1.3-6.6, P = .009] and spine BMD gain during Dmab therapy corrected for the number of Dmab injections (OR 3.0, IQR 1.2-7.2, P = .014). A CTX level at t1 > 212 ng/L had 100% sensitivity in predicting the BMD loss. CONCLUSION: In patients with uncontrolled CTX levels after Dmab withdrawal, 2 ZOL infusions 6 months apart do not prevent BMD loss and FX.
引用
- Grassi G, Ghielmetti A, Zampogna M, et al. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion? J Clin Endocrinol Metab. 2024. PMID: 38609157. doi:10.1210/clinem/dgae224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。